LABELS · 19da1322-c3d0-4527-acce-95766b7e2dc7

levothyroxine sodium

Open original source → · Download preserved record

Preserved label snapshot, not confirmation of a current approved indication. Approval/withdrawal status must be checked for the exact disease, setting and regimen.

Label effective date: 2025-07-15
Captured: 2026-09-09T23:37:39.774134+00:00
Current indication reconciliation: Not reconciled

Boxed warning in this label

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions ( 6 ) , Drug Interactions ( 7.7 ) , and Overdosage ( 10 )] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including Levothyroxine Sodium Tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity ( 6 , 10 ).

Indications and usage: exact source text

1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

Full extracted label fields

application numbers

NDA021116

boxed warning exact

WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS Thyroid hormones, including Levothyroxine Sodium Tablets, either alone or with other therapeutic agents, should not be used for the treatment of obesity or for weight loss. In euthyroid patients, doses within the range of daily hormonal requirements are ineffective for weight reduction. Larger doses may produce serious or even life threatening manifestations of toxicity, particularly when given in association with sympathomimetic amines such as those used for their anorectic effects [see Adverse Reactions ( 6 ) , Drug Interactions ( 7.7 ) , and Overdosage ( 10 )] . WARNING: NOT FOR TREATMENT OF OBESITY OR FOR WEIGHT LOSS See full prescribing information for complete boxed warning • Thyroid hormones, including Levothyroxine Sodium Tablets should not be used for the treatment of obesity or for weight loss. • Doses beyond the range of daily hormonal requirements may produce serious or even life threatening manifestations of toxicity ( 6 , 10 ).

brand names

levothyroxine sodium

current indication status

not_reconciled

dailymed set url

https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=398a00d0-1247-4f6f-b4c1-dade399cc417

generic names

LEVOTHYROXINE SODIUM

19da1322-c3d0-4527-acce-95766b7e2dc7

indications and usage exact

1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.

indications and usage tables exact

is original packager

manufacturer names

Preferred Pharmaceuticals, Inc.

matched search terms

cancer

package ndcs

68788-7689-3
68788-7689-9

product ndcs

68788-7689

product types

HUMAN PRESCRIPTION DRUG

recent major changes exact

record type

complete_spl_indications_section_candidate

routes

ORAL

rxcuis

966224

source batch

file

/private/tmp/cancer-full-research/indications/raw/labels-00000.json

meta

disclaimer

Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.

last updated

2026-09-09

license

https://open.fda.gov/license/

results

limit: 100
skip: 0
total: 830

terms

https://open.fda.gov/terms/

sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

url

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl effective time

20250715

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

substance names

LEVOTHYROXINE SODIUM

uniis

9J765S329G

verification flags

oncology_keyword_candidate_not_clinically_classified
spl_text_not_verified_identical_to_latest_approved_label
individual_indications_not_split_or_reconciled
not_identified_as_original_packager

Drugs@FDA application source records

application number
NDA021116
payload
all indexed label documents
Appl No
021116
Application Docs Date
2002-10-24 00:00:00
Application Docs ID
36151
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/21116lbl.pdf
Submission No
1
Submission Type
ORIG
Appl No
021116
Application Docs Date
2006-03-14 00:00:00
Application Docs ID
36152
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2006/021116s006lbl.pdf
Submission No
6
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2017-09-01 00:00:00
Application Docs ID
49659
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021116s013lbl.pdf
Submission No
13
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2019-04-25 00:00:00
Application Docs ID
58413
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2019/021116s017lbl.pdf
Submission No
17
Submission Type
SUPPL
Appl No
021116
Application Docs Date
2023-11-17 00:00:00
Application Docs ID
76605
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021116s027lbl.pdf
Submission No
27
Submission Type
SUPPL
all submission records
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
27
Submission Status
AP
Submission Status Date
2023-11-16 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
23
Submission Status
AP
Submission Status Date
2022-04-14 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
21
Submission Status
AP
Submission Status Date
2021-12-13 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
17
Submission Status
AP
Submission Status Date
2019-04-23 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
2
Submission No
16
Submission Status
AP
Submission Status Date
2016-05-19 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
14
Submission Status
AP
Submission Status Date
2015-11-09 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
13
Submission Status
AP
Submission Status Date
2017-08-31 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
12
Submission Status
AP
Submission Status Date
2015-01-13 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
3
Submission No
6
Submission Status
AP
Submission Status Date
2006-03-10 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
4
Submission No
4
Submission Status
AP
Submission Status Date
2004-12-07 00:00:00
Submission Type
SUPPL
Submissions Public Notes
Appl No
021116
Review Priority
STANDARD
Submission Class Code ID
15
Submission No
1
Submission Status
AP
Submission Status Date
2002-10-24 00:00:00
Submission Type
ORIG
Submissions Public Notes
application number
NDA021116
approval interpretation
Application linkage and approved submission are not indication-level current approval verification
current indication status
not_reconciled
drugsfda url
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=021116
has approved submission record
true
latest approved submission date
2023-11-16
latest label selection rule
max FDA ApplicationDocsDate, including all ties; posting date is not approval date and latest indexed document may be incomplete
latest posted label documents
Appl No
021116
Application Docs Date
2023-11-17 00:00:00
Application Docs ID
76605
Application Docs Title
0
Application Docs Type ID
2
Application Docs URL
http://www.accessdata.fda.gov/drugsatfda_docs/label/2023/021116s027lbl.pdf
Submission No
27
Submission Type
SUPPL
official application record
Appl No
021116
Appl Public Notes
Appl Type
NDA
Sponsor Name
ALVOGEN
openfda application present
true
products
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
001
Reference Drug
1
Reference Standard
0
Strength
0.025MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
002
Reference Drug
1
Reference Standard
0
Strength
0.05MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
003
Reference Drug
1
Reference Standard
0
Strength
0.075MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
004
Reference Drug
1
Reference Standard
0
Strength
0.1MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
005
Reference Drug
1
Reference Standard
0
Strength
0.125MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
006
Reference Drug
1
Reference Standard
0
Strength
0.15MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
007
Reference Drug
1
Reference Standard
0
Strength
0.175MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
008
Reference Drug
1
Reference Standard
0
Strength
0.2MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
009
Reference Drug
1
Reference Standard
0
Strength
0.3MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
010
Reference Drug
1
Reference Standard
0
Strength
0.088MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
011
Reference Drug
1
Reference Standard
0
Strength
0.112MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription
Active Ingredient
LEVOTHYROXINE SODIUM
Appl No
021116
Drug Name
THYRO-TABS
Form
TABLET;ORAL
Product No
012
Reference Drug
1
Reference Standard
0
Strength
0.137MG **See current Annual Edition, 1.8 Description of Special Situations, Levothyroxine Sodium
marketing status
Prescription

Source passages and status connections

Passage classifications are automated and are not treatment recommendations. Connections apply only to their recorded indication scope.

Passage 1 · indication intro context

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement
incomplete_colon_led_indication_intro

clinical review status

pending

content role

indication_intro_context

context span

end: 288
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimu
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 0

current approval status

not_reconciled

duplicate text group

dup-bbbf413f1c5821aaf88f

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-90f1efb3d58528153ac2

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

end: 83
end exclusive: true
exact text: are L-thyroxine (T4) indicated
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 53

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 88
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for:
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 0

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 2 · unclassified context

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 443
end exclusive: true
exact text: 1 INDICATIONS AND USAGE Levothyroxine Sodium Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid c
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 0

current approval status

not_reconciled

duplicate text group

dup-8fdc7ba760ac087a7e13

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-b88be4ea3ee77afb2272

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 243
end exclusive: true
exact text: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 89

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 3 · unclassified context

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 449
end exclusive: true
exact text: Tablets are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 44

current approval status

not_reconciled

duplicate text group

dup-6574288ceced57989d25

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-3c0ec125a2c78c1e78b1

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 249
end exclusive: true
exact text: ( 1 )
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 244

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 4 · unclassified context

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

no_unambiguous_positive_indication_predicate

clinical review status

pending

content role

unclassified_context

context span

end: 649
end exclusive: true
exact text: ts are L-thyroxine (T4) indicated for: • Hypothyroidism: As replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. ( 1 ) • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during t
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 50

current approval status

not_reconciled

duplicate text group

dup-9d76f98bb669698c7f45

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-a5dc3dc74395c6cd82e5

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 449
end exclusive: true
exact text: • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 250

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

unclear

Passage 5 · limitation of use

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 891
end exclusive: true
exact text: • Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression: As an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. ( 1 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pi
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 250

current approval status

not_reconciled

duplicate text group

dup-86b86b28519d720600e0

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-3e20cfbfd0f5a41566d8

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 691
end exclusive: true
exact text: ( 1 ) Limitations of Use: - Not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 450

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 6 · positive indication candidate

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

explicit_positive_indication_predicate
no_tumor_directed_keyword_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1088
end exclusive: true
exact text: for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients. - Not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-depen
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 492

current approval status

not_reconciled

duplicate text group

dup-a77b289f2e1274e660ce

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-98e473cf325fae1afd48

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

end: 749
end exclusive: true
exact text: are indicated
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 736

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 888
end exclusive: true
exact text: Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 692

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

non_oncology_or_unclear_candidate

Passage 7 · positive indication candidate

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

explicit_positive_indication_predicate
tumor_or_malignant_hematology_words_in_positive_statement

clinical review status

pending

content role

positive_indication_candidate

context span

end: 1328
end exclusive: true
exact text: s. Hypothyroidism Levothyroxine Sodium Tablets are indicated as a replacement therapy in primary (thyroidal), secondary (pituitary), and tertiary (hypothalamic) congenital or acquired hypothyroidism. Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benef
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 689

current approval status

not_reconciled

duplicate text group

dup-d873958155f2cc904006

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-e206323a55f16e2df064

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

end: 1000
end exclusive: true
exact text: are indicated
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 987

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1128
end exclusive: true
exact text: Pituitary Thyrotropin (Thyroid-Stimulating Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 889

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

tumor_directed_candidate

Passage 8 · limitation of use

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

limitation_heading

clinical review status

pending

content role

limitation_of_use

context span

end: 1348
end exclusive: true
exact text: ng Hormone, TSH) Suppression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatmen
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 929

current approval status

not_reconciled

duplicate text group

dup-78b77a3081b27a66d902

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-6da122d3210ed453321b

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1148
end exclusive: true
exact text: Limitations of Use:
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 1129

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 9 · limitation of use

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1582
end exclusive: true
exact text: pression Levothyroxine Sodium Tablets are indicated as an adjunct to surgery and radioiodine therapy in the management of thyrotropin-dependent well-differentiated thyroid cancer. Limitations of Use: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 949

current approval status

not_reconciled

duplicate text group

dup-30f6e1bfa148954cf3c9

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-a41e2240cf2da4e4541d

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1450
end exclusive: true
exact text: • Levothyroxine Sodium Tablets are not indicated for suppression of benign thyroid nodules and nontoxic diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )].
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 1149

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Passage 10 · limitation of use

application numbers

NDA021116

brand names

levothyroxine sodium

classification reasons

negative_or_not_established_clause

clinical review status

pending

content role

limitation_of_use

context span

end: 1582
end exclusive: true
exact text: c diffuse goiter in iodine-sufficient patients as there are no clinical benefits and overtreatment with Levothyroxine Sodium Tablets may induce hyperthyroidism [see Warnings and Precautions ( 5.4 )]. • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 1251

current approval status

not_reconciled

duplicate text group

dup-30bfe42c0c64097a4028

extraction review status

automated_candidate_pending_source_review

generic names

LEVOTHYROXINE SODIUM

ind-span-5f83ed7aa2a2efb9cfcb

label id

19da1322-c3d0-4527-acce-95766b7e2dc7

positive predicate support span

Source null

qualifier mentions

regulatory links

schema version

0.1.0

source batch sha256

0dba7a040bbbf460aa9f482c5b67c9f28f75fc9df775ee1e7b345b758f780e07

source defined aliases

source span

end: 1582
end exclusive: true
exact text: • Levothyroxine Sodium Tablets are not indicated for treatment of hypothyroidism during the recovery phase of subacute thyroiditis.
label id: 19da1322-c3d0-4527-acce-95766b7e2dc7
offset unit: unicode_code_points
source array index: 0
source field: indications_and_usage_exact
source text sha256: beeaa755483012e413716a4a75f3ff5fcbe2e46138c21321da8fa861096178b4
start: 1451

source url

https://api.fda.gov/drug/label.json?search=id%3A%2219da1322-c3d0-4527-acce-95766b7e2dc7%22

spl effective date

2025-07-15

spl set id

398a00d0-1247-4f6f-b4c1-dade399cc417

spl version

structured fields status

not_extracted_no_values_inferred_from_mentions

structured indication

age: Source null
approval pathway: Source null
biomarker and test: Source null
disease stage: Source null
limitations: Source null
line: Source null
prior therapy: Source null
regimen: Source null
tumor histology: Source null

use intent

not_applicable

Preserved source evidence · Not medical advice